Early access
Sign in
Enrolling by invitationNo phase

Checking Blood Sugar Tests for Diabetes in Adults Over 65

Studies A1c tests and glucose monitors in adults over 65.

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis
Status
Enrolling by invitation
People taking part
45 people, planned
Started
1 Dec 2025
Expected to end
1 Mar 2027
Type of study
Observational
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 65 or older whose A1c test results do not agree with their blood sugar levels. They have no diabetes diagnosis or treatment.

Age
65 years or older
Sex
All sexes can join
Disease stage
A1c between 5.3% (34 mmol/mol) and 7.4% (57 mmol/mol), no diabetes on the problem list, no current or past diabetes treatment, and A1c results that do not agree with blood sugar (found by an EHR-based algorithm)
Earlier treatment
No current or past treatment for diabetes
Biomarker or test result
At least 5 HbA1c values and 3 CBC values in the electronic health record over the previous 10 years

Main reasons for not taking part

  • Diabetes of other causes (type 1, pancreatogenic, monogenic, etc.)
  • Clinically significant anemia based on recent hematocrit or hemoglobin
  • Blood cancer
  • Active or planned cancer treatment that could interfere with the study
  • Taking agents that interfere with the CGM sensor, such as high dose vitamin C

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age 65 years of age or older
  • A1c 5.3% - 7.4% without a diagnosis on the problem list and/or current or prior treatment for diabetes
  • Evidence of A1c discordance by meeting one of two criteria developed by an EHR based algorithm
  • At least five (5) HbA1c values and three (3) CBC values available in the EHR in the previous 10 years
  • Willingness to wear an Abbott Freestyle Libre 3 System Sensor for up to 48 days
  • Willingness to consent to data collection using the electronic health record and sign a medical release to obtain future medical records from other health care facilities

Who cannot take part

  • Active treatment for cancer, planned treatment for cancer, or recent active cancer with a likelihood of recurrence or progression, that, in the opinion of the site investigator, would interfere with study therapy prior to 2029; Allowed Exceptions: Treated cancer with no evidence of disease, no evidence of disease progression, and no planned change in therapy. Examples of allowable cancers include:; Breast cancer stable after active treatment, managed with long-term anti-estrogen therapy; Prostate cancer being observed; Stage 0 or 1 tumors status post resection or other definitive treatment; Other similarly stable cancer comorbidities
  • Known or suspected diabetes of other causes (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.)
  • Condition with short life expectancy
  • Blood (hematologic) malignancy
  • Unstable psychiatric or medical condition
  • Clinically significant anemia based on most recent hematocrit (M = <38%, F <33%) and/or hemoglobin (M = <12 g/dL, F = <10 g/dL) within the last 12 months
  • rtCGM-interference agents per manufacturer (e.g., high dose vitamin C)

Where in United States

  • Brigham and Women's HospitalBoston, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The goal of this observational study is to learn why some adults over the age of 65, have A1c tests that do not match up with their blood glucose levels, also known as 'A1c-glucose discordance'.

Read full original descriptionShow less

The main question it aims to answer is:

Could alternative tests like CGM or personalized A1c provide more accurate diabetes screening in this population?

Participants will be asked to perform blood tests every week to two weeks and wear a CGM for up to 8 weeks.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis (PRECISE DM Dx)
Plain-language title
Checking Blood Sugar Tests for Diabetes in Adults Over 65Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 October 2026